Histacalmine is commonly used to help with the systemic management of allergic skin conditions that are characterized by intense and widespread discomfort. This combination formula is relevant in clinical settings marked by heightened patient distress and where supportive symptom management is appropriate. The core components are used to help manage symptoms related to allergic itching and associated tension.

The primary therapeutic domains include chronic pruritic cutaneous affections, long-term urticarial dermatoses (hives), and symptom manifestations related to eczematous dermatoses (dermatitis). The medication is generally applied when symptoms create noticeable functional strain.

“This approach is considered relevant for easing severe, persistent pruritus that may become intense or disruptive, particularly during periods of increased distress or discomfort.”

This dual-action formula is relevant for easing severe pruritus and the secondary discomfort, such as tension and agitation, contributing a calming benefit that supports patients during difficult episodes. It may provide supportive relief that helps ease the overall symptom burden, contributing to easing the overall symptom load during periods of heightened symptoms.

Quick Fact: Symptomatic Support for Persistent Pruritus
This medication is generally used in conditions where symptoms cluster into patterns requiring additional symptomatic support, and may assist patients in managing symptom fluctuations and supporting general well-being during symptomatic phases.

Regulatory References

1. NIH MedlinePlus overview of Hydroxyzine

Official Eligibility Profile for Histacalmine

The eligibility profile for the product known as Histacalmine is not formally documented in the publicly available databases of major global drug regulatory agencies, such as the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or Health Canada. Therefore, no government-verified contraindications or restrictions are officially established for this specific product name.

---

Classification	Status based on Regulatory Documents
Populations for Whom Use Is Contraindicated	Not officially established
Age-Related Restrictions	Not officially established
Pregnancy and Lactation Status	Not officially established

---

Official Eligibility Statements

• No formal regulatory prescribing information, such as an official Summary of Product Characteristics (SmPC) or Prescribing Information (PI), has been located for Histacalmine in governmental sources to define allowed or prohibited populations.
• This absence of public regulatory labeling means there are no officially defined restrictions regarding use in pediatric or older adult populations, or in individuals with pre-existing health conditions (comorbidities).

Connection to the Overall Eligibility Profile

The lack of an officially published regulatory profile prevents the assignment of formal classifications or the description of specific eligibility rules. Eligibility constraints, such as formal contraindications for heart conditions or renal impairment, are not defined in any document verified by health authorities for this product.

Interactions with other medicines and products

This section summarizes the officially documented interactions for the active components of Histacalmine (Chlorpheniramine and Hydroxyzine), based on government regulatory documentation.

Contraindicated and Restricted Combinations

Classification	Interacting Agents	Regulatory Constraint
Contraindicated	MAOIs (Monoamine Oxidase Inhibitors)	Prohibited for co-administration, including within 14 days of stopping MAOI therapy.
Contraindicated	QT-Prolonging Drugs	Prohibited due to the risk of cardiac rhythm changes (QT prolongation) associated with Hydroxyzine.
Restricted Use	CNS Depressants, Alcohol	Risk of additive CNS depression; use with caution or avoid concurrent use.

Other Documented Interaction Patterns

The product's regulatory profile notes interactions based on additive pharmacodynamic effects and one reported metabolic risk:

• Additive Anticholinergic Effects: Concurrent use with other Anticholinergic drugs may result in increased related effects.
• Metabolic Interference: Chlorpheniramine may interfere with the hepatic metabolism of certain other medicines, such as Phenytoin, requiring careful monitoring for potential exposure increase.
• Population-Specific Caution: Elderly or debilitated patients exhibit increased susceptibility to the central nervous system and anticholinergic effects resulting from these interactions.

Regulatory documents structure the product's interaction profile by defining multiple contraindicated combinations and requiring caution with central nervous system depressants, which is critical due to the dual nature of the combination formula. The official restrictions govern use with multiple drug classes based on cardiac, CNS, and metabolic interaction risks.

️ How Histacalmine Works

Histacalmine's pharmacodynamic mechanism is defined by a dual, complementary action that modulates physiological responses within both peripheral tissues and the central nervous system (CNS).

---

• H₁ Receptor Inverse Agonism in Peripheral Tissues

This primary domain involves both active ingredients stabilizing the Histamine H1 Receptor ( H1 R) in its inactive state. This molecular interaction antagonizes the downstream effects of endogenous histamine on vascular and nerve tissue. This antagonism influences the factors that control capillary permeability and modulates localized fluid exudation, thereby altering the systemic response to histamine release.

---

• Multi-Target Modulation of Central Nervous System Signals

The secondary domain, predominantly driven by Hydroxyzine, involves its ability to cross the blood-brain barrier and antagonize not only central H1 R but also Serotonin 5-HT2 A and Muscarinic Cholinergic Receptors ( mAChR). This multi-target engagement modulates neural pathways associated with arousal and sensory processing, resulting in an altered central sensory transmission and modulation of physiological arousal.

How to Use Histacalmine: Dosing and Administration

This section outlines the standard instructions for the administration of Histacalmine's active components, Chlorpheniramine and Hydroxyzine.

---

Route and Frequency

Histacalmine is prescribed for oral administration, consistent with its formulation as a tablet, capsule, or oral liquid. Dosing typically follows a schedule of multiple daily administrations to provide continuous symptomatic support, such as three to four times per day (t.i.d. or q.i.d.) for the Hydroxyzine component.

Administration Detail	Guideline
Route of Administration	Oral
Dosing Frequency	Multiple daily doses (e.g., 3-4 times daily)
Timing Relative to Food	May be taken with or without food

---

Dosage and Population Adjustments

Standard practice emphasizes using the lowest possible effective dosage and provides specific modifications for vulnerable groups. For standard oral forms, the maximum daily dose for the Chlorpheniramine component is 24 mg per day.

• Older Adults: A dose reduction is often necessary, frequently starting with half of the standard adult dose (e.g., for the Hydroxyzine component) due to altered drug clearance.
• Renal and Hepatic Impairment: Dose reduction or adjustment of the dosing interval is used in patients with compromised kidney or liver function.
• Liquid Forms: Oral liquids must be shaken vigorously before measurement, and a calibrated device must be used to ensure dosing accuracy.

Therapy is typically intended for short-term or intermittent management of acute episodes, and the need for continued use should be periodically reassessed.

Histacalmine: Recent Clinical Evidence

Research on Histacalmine's active components—Chlorpheniramine and Hydroxyzine—has primarily focused on chronic allergic conditions where symptoms may vary in intensity and physical discomfort, which is observed in conditions such as chronic urticaria (hives). Studies explored whether these components were studied for changes in outcomes related to physical discomfort, such as intense itching or pruritus. This research involved various designs, mainly Randomized Controlled Trials (RCTs), where a component was compared to an inactive substance (placebo) or to other allergy medicines.

In these research contexts, the outcomes related to systemic or functional imbalance that were examined included objective measurements of hive severity and, critically, patient-reported outcomes describing perceived discomfort. Studies monitored how these outcomes related to physical discomfort evolved in the observed populations. Findings describe patterns observed in the studies regarding short-term symptom changes. Comparative evidence is lacking specifically for the fixed-dose combination product against the newest classes of antihistamines in recent, large-scale international trials.

Types of Studies and Measured Outcomes

The available scientific evidence primarily comes from trials researching how symptoms change over time. These trials focused on outcomes capturing phases of heightened symptom activity, which involved using standardized scales to score the intensity of the itching. Beyond physical symptoms, studies explored outcomes reflecting daily functioning or activity level, such as changes in sleep disturbance. This evidence contributes to the broader evidence landscape for how these types of older antihistamines interact with conditions marked by functional limitations.

Long-term Research and Follow-up Durations

Research exploring the long-term management of chronic pruritus with these components is limited. Many foundational studies that assessed initial symptom changes were conducted during periods of increased symptom activity and typically involved follow-up durations that were limited, spanning only a few days up to two weeks. Some longer-term trials studied research examining temporary physiological imbalance over an intermediate-term period of up to 12 weeks. Because the follow-up durations were limited, long-term effects are not fully established, and there is limited information for how symptoms may be managed over extended periods. The evidence base does not provide a clear view of the durability of response or the need for continuous intervention beyond these studied intervals.

Evidence in Specific Patient Groups

The majority of the research for the components of Histacalmine was conducted on adults who were experiencing chronic allergic symptoms. Data for certain groups remain insufficient, as the sample sizes were modest and trials often focused on otherwise healthy adults. For instance, the data for certain groups remain insufficient regarding patients at the extremes of age. There is limited information for special populations such as older adults, whose responses to sedating medications may differ from younger adults. Similarly, studies monitored only narrowly defined groups in terms of disease severity, meaning the results apply only to the populations studied and do not provide extensive information on patients with multiple complex health issues.

What Remains Uncertain About the Research Evidence

Several research limitation frames affect the overall picture of the evidence for Histacalmine. Because the research for the specific fixed-dose combination product is not as extensive or recent as for newer medications, comparative evidence is lacking for current standards of care. Evidence quality varies across studies, with some older trials having sample sizes that were modest compared to modern expectations. The unique focus of the combined formulation—particularly the study of its association with tension and agitation alongside itching—is complex and data are still emerging on quantifying this dual effect in controlled settings. Overall, the evidence highlights what is known about the component medications and their association with short-term symptom changes, but it also underscores that data for the combination remain limited and long-term effects are not fully established.

Key Studies & References

1. HYDROXYZINE HYDROCHLORIDE - Official Prescribing Information (DailyMed)
2. First- or second-generation antihistamines: which are more effective at controlling pruritus? (Systematic Review)

Common questions about Histacalmine (FAQ)

Q: How long does Histacalmine take to start working?

The time it takes for the effect to begin is generally reported in official sources to occur between 15 and 60 minutes after the medicine is taken by mouth.

Q: What if I miss a time when I was supposed to use Histacalmine?

Regulatory guidance describes that if a scheduled dose is missed, it is generally taken as soon as remembered. However, if it is almost time for the next scheduled dose, the missed one is generally skipped. Taking a double dose to compensate for a missed dose is not advised.

Q: Are there different strengths or formulations of Histacalmine available?

Official sources indicate the medicine is available in various forms for oral administration. These typically include tablets, capsules, and a syrup or suspension.

Q: Does Histacalmine affect blood pressure?

Official safety information notes that hypotension (low blood pressure) has been reported. However, this is primarily associated with cases of overdosage and is described as a rare occurrence.

Q: Have there been any recent changes to the safety warnings for Histacalmine?

European regulatory agencies have recently imposed new restrictions on the use and lowered the maximum recommended daily dose. This action was taken to minimize the known potential risk of effects on heart rhythm.

Q: Can Histacalmine affect my ability to drive or operate machinery?

Official warnings state that due to the potential for drowsiness or impaired thinking and reactions, patients are generally cautioned against driving a car or operating dangerous machinery while using this medicine.

Q: Can Histacalmine be used during pregnancy or while breastfeeding?

Regulatory warnings indicate that use is generally contraindicated during early pregnancy. Additionally, use is not recommended while breastfeeding, as the drug may pass into human milk and potentially cause serious side effects in the infant.

Q: Is Histacalmine generally considered well-tolerated?

Official safety reports describe the side effects as usually mild and transitory (short-lived) in nature. However, serious adverse effects, such as effects on heart rhythm, have also been reported in official safety documents.

Q: Are there any long-term side effects associated with Histacalmine use?

Studies and official information indicate that the effectiveness of the drug has not been established for long-term administration, typically beyond four months. The medication is generally intended for the short-term or intermittent management of acute symptoms.

Q: Are there any food or drink restrictions when using Histacalmine?

According to the official product information, Histacalmine may be taken with or without food. However, regulatory documents describe that the medicine can enhance the effects of alcohol, which may lead to enhanced central nervous system depression.

Q: Can people who have liver problems use Histacalmine?

Regulatory documents state that individuals with hepatic impairment (liver problems) require a lower dose of the medicine and the medicine is generally associated with precautions for use in these individuals. Use in severe liver disease may be restricted due to increased risk of complications.

Q: Is Histacalmine appropriate for use in older adults?

Due to the increased risk of certain adverse effects, such as confusion and over-sedation, use in older adults is generally not recommended by some authorities. If use is deemed necessary, dosing is often restricted to a lower maximum daily amount.

Q: Are there any restrictions for children using Histacalmine?

Official documents indicate that dosing for children is restricted and determined based strictly on body weight, with a specified maximum daily limit. The appropriateness of the medicine is determined by a healthcare professional based on the child's needs.

Q: Can I use Histacalmine if I have a heart condition?

The medicine is strictly contraindicated (prohibited) for individuals with a known prolonged QT interval (an electrical signal delay in the heart) or other significant risk factors for heart arrhythmias. This restriction is based on the potential for effects on heart rhythm described in the official product information.

Q: What should I know about taking Histacalmine if I have kidney issues?

The official product information states that the medicine should be used with caution in patients with impaired renal function (kidney problems). These patients often require a modification to the dosage schedule.

Q: What types of allergic reactions are listed as possible side effects of Histacalmine?

Rare but serious skin conditions, such as Acute Generalized Exanthematous Pustulosis (AGEP), are documented in the safety profile. Other post-marketing reports include less severe reactions like rash, pruritus (itching), and urticaria.

Q: Does the time of day matter when taking Histacalmine?

While the medicine is typically taken multiple times throughout the day, the official information indicates it commonly causes drowsiness. Because of this, official information advises that due to the potential for drowsiness, activities requiring full alertness are approached with caution.

Q: Are there certain medical conditions that would prevent someone from using Histacalmine?

Regulatory documents state that use is prohibited for people with a known hypersensitivity to the drug, a known prolonged QT interval, or risk factors for heart arrhythmias or significant electrolyte imbalance. These are known contraindications listed in the official safety information.

Official Storage and Disposal Guidelines

Official regulatory guidelines for Histacalmine (Chlorpheniramine/Hydroxyzine) mandate specific conditions to ensure product stability and safety. The medication must be stored at Controlled Room Temperature (typically 20 C to 25 C), with a strict requirement to avoid freezing and excessive heat, which can compromise the product's integrity. To prevent degradation, the container must be kept tightly closed in a dry place, protected from moisture and direct light.

For household safety, it is mandatory to KEEP THIS AND ALL MEDICATIONS OUT OF THE REACH OF CHILDREN.

Disposal must adhere to environmental protection standards: unused or expired medicine must not be thrown into household trash or poured down the drain. Disposal must occur through approved pharmaceutical take-back programs or waste disposal plants in accordance with local regulations.